What is BioEclipse Therapeutics?
BioEclipse Therapeutics is a clinical-stage biopharmaceutical company dedicated to pioneering next-generation immunotherapies for advanced cancer patients who have exhausted conventional treatment options. Their core innovation lies in a proprietary allogeneic platform engineered to leverage both innate and adaptive immune responses. This technology aims to effectively target and eradicate solid tumors, which represent the vast majority of cancer diagnoses. With lead candidates such as CRX200 and CRX100, BioEclipse Therapeutics is focused on delivering cost-effective, engineered immune solutions with demonstrated potency against a spectrum of tumor types. The company's overarching mission is to achieve complete disease eradication and establish durable, tumor-specific immune memory in patients battling resistant and recurrent solid tumors.
How much funding has BioEclipse Therapeutics raised?
BioEclipse Therapeutics has raised a total of $7.7M across 1 funding round:
Other Financing Round
$7.7M
Other Financing Round (2019): $7.7M with participation from Revelis Capital Group , LLC
Key Investors in BioEclipse Therapeutics
Revelis Capital Group , LLC
Revelis Capital Group, LLC is an investment firm that has participated in BioEclipse Therapeutics' funding rounds. Further details on their specific investment focus or typical stage preference are not available from the provided data.
What's next for BioEclipse Therapeutics?
The substantial enterprise-level funding and recent strategic investment position BioEclipse Therapeutics for accelerated clinical development and potential commercialization of its novel immunotherapies. This capital infusion is expected to fuel the advancement of its pipeline, particularly CRX200 and CRX100, through critical clinical trials. The company's focus on solid tumors and engineered immune solutions addresses a significant unmet medical need, suggesting a strategic expansion into a high-growth market segment. Future endeavors will likely involve further validation of their allogeneic platform's efficacy and safety, potentially attracting additional strategic partnerships or follow-on financing rounds to support long-term growth and market penetration.
See full BioEclipse Therapeutics company page
